A recent longitudinal study using SPECT found reduced DAT binding at baseline in 50% of subjects, a more rapid rate of decline in DAT binding in RBD subjects compared to controls, and the emergence of PD in 3/20 RBD patients (those with the lowest DAT binding) over the follow-up period of 3 years [62]. This evidence concerns the gene SLC6A3 and Parkinson disease.